Clinical outcome of patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) treated with pembrolizumab.

被引：3
|
作者：
Sinicrope, Frank A. [1 ]
Chakrabarti, Sakti [1 ]
Eiring, Rachel [1 ]
Mitchelll, Jessica L. [1 ]
Finnes, Heidi D. [1 ]
Hubbard, Joleen Marie [1 ]
McWilliams, Robert R. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e24127
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e24127
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): Updated results from KEYNOTE-158
    O'Malley, D.
    Bariani, G. M.
    Cassier, P. A.
    Marabelle, A.
    Hansen, A. R.
    Acosta, A. De Jesus
    Miller, W. H., Jr.
    Safra, T.
    Italiano, A.
    Mileshkin, L.
    Xu, L.
    Jin, F.
    Norwood, K.
    Maio, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S730 - S731
  • [22] Histologic Subtypes of Microsatellite Instability-High (MSI-H) Colorectal Adenocarcinomas (CRCs) and Their Association with Clinicopathologic Features and Prognosis
    Agarwal, A.
    Sethi, S.
    Lin, E.
    Luthra, R.
    Rashid, A.
    Hamilton, S. R.
    Eng, C.
    Maru, D. M.
    MODERN PATHOLOGY, 2010, 23 : 134A - 134A
  • [23] Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the KEYNOTE-177 study Asia subgroup
    Yoshino, T.
    Andre, T.
    Kim, T. W.
    Yong, W. P.
    Shiu, K-K.
    Jensen, B. Vittrup
    Jensen, L. H.
    Punt, C. J. A.
    Smith, D.
    Garcia-Carbonero, R.
    Alcaide-Garcia, J.
    Gibbs, P.
    de la Fouchardiere, C.
    Rivera, F.
    Elez Fernandez, M. E.
    Le, D. T.
    Zuo, Y.
    Fogelman, D.
    Adelberg, D. E.
    Diaz, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1502 - S1503
  • [24] Histologic Subtypes of Microsatellite Instability-High (MSI-H) Colorectal Adenocarcinomas (CRCs) and Their Association with Clinicopathologic Features and Prognosis
    Agarwal, A.
    Sethi, S.
    Lin, E.
    Luthra, R.
    Rashid, A.
    Hamilton, S. R.
    Eng, C.
    Maru, D. M.
    LABORATORY INVESTIGATION, 2010, 90 : 134A - 134A
  • [25] Genomic characterization and translational immunotherapy of microsatellite instability-high (MSI-H) in cholangiocarcinoma.
    Yang, Xu
    Lian, Baofeng
    Li, Yiran
    Xue, Jinnan
    Wang, Yunchao
    Wang, Yanyu
    Xun, Ziyu
    Zhang, Nan
    Sun, Huishan
    Long, Junyu
    Song, Zhijian
    Lu, Leilei
    Pan, Jie
    Zhao, Lin
    Guan, Mei
    Yang, Xiaobo
    Mao, Yilei
    Sang, Xinting
    Wang, Kai
    Zhao, Hai-Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.
    Overman, Michael J.
    Kopetz, Scott
    McDermott, Raymond S.
    Leach, Joseph
    Lonardi, Sara
    Lenz, Heinz-Josef
    Morse, Michael A.
    Desai, Jayesh
    Hill, Andrew
    Axelson, Michael D.
    Moss, Rebecca Anne
    Lin, Chen-Sheng
    Goldberg, Monica
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Nivolumab in patients with DNA mismatch repairdeficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.
    Overman, Michael J.
    Bergamo, Francesca
    McDermott, Raymond S.
    Aglietta, Massimo
    Chen, Franklin
    Gelsomino, Fabio
    Wong, Mark
    Morse, Michael
    Van Cutsem, Eric
    Hendlisz, Alain
    Neyns, Bart
    Moss, Rebecca Anne
    Zhao, Huanyu
    Cao, Z. Alexander
    Kamble, Shital
    Kopetz, Scott
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [28] Pembrolizumab (pembro) for previously treated, microsatellite instabilityehigh (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Final analysis of KEYNOTE-164
    Le, D. T.
    Diaz, L.
    Kim, T. W.
    Van Cutsem, E.
    Geva, R.
    Jager, D.
    Hara, H.
    Burge, M.
    O'Neil, B.
    Kavan, P.
    Yoshino, T.
    Guimbaud, R.
    Taniguchi, H.
    Elez, E.
    Al-Batran, S-E.
    Boland, P.
    Cui, Y.
    Leconte, P.
    Marinello, P.
    Andre, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S550 - S550
  • [29] Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study
    Shiu, K. K.
    Andre, T.
    Kim, T. W.
    Jensen, B. Vittrup
    Jensen, L. H.
    Punt, C. J. A.
    Smith, D.
    Garcia-Carbonero, R.
    Alcaide-Garcia, J.
    Gibbs, P.
    De la Fouchardiere, C.
    Rivera, F.
    Fernandez, M. E. Elez
    Le, D. T.
    Yoshino, T.
    Zuo, Y.
    Fogelman, D.
    Adelberg, D. E.
    Diaz, L. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1271 - S1272
  • [30] Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer
    Chakrabarti, Sakti
    Bucheit, Leslie
    Starr, Jason Scott
    Innis-Shelton, Racquel
    Shergill, Ardaman
    Dada, Hiba
    Resta, Regina
    Wagner, Stephanie
    Fei, Naomi
    Kasi, Pashtoon Murtaza
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (06)
12345